The repositioning or “repurposing” of existing therapies for alternative disease indications is
an attractive approach that can save significant investments of time and money during drug …

Cancer poses a significant global health challenge, with predictions of increasing
prevalence in the coming years due to limited prevention, late diagnosis, and inadequate …

The discovery of drug compounds has a long history in drug repurposing, notably by
fortuitous findings. It has taken a new path in the creation of novel therapeutics based on …

Drug repurposing refers to the identification of clinically approved drugs with the known
safety profiles and defined pharmacokinetic properties for new indications. Despite the …

Why is this a timely topic for the oncology community? The cost of new cancer drugs is
increasing rapidly and is currently in the range of $100,000 to $150,000 per year. Thus, this …

High rates of failure, exorbitant costs, and the sluggish pace of new drug discovery and
development have led to a growing interest in repurposing “old” drugs to treat both common …

Increasing costs, much time consumption and high risk of failure associated with the process
of de novo development of new anticancer drugs have prompted the pharmaceutical …

Human malignancies are one of the major health-related issues though out the world and
anticipated to rise in the future. The development of novel drugs/agents requires a huge …

The repurposing of existing non-cancer drugs is a potential source of new treatment options
for cancer patients with high unmet medical needs. While scientific research is progressing …

Drug repurposing or repositioning has been well-known to refer to the therapeutic
applications of a drug for another indication other than it was originally approved for …